Momotaro-Gene
Momotaro-Gene is a private, clinical-stage biotherapeutics company developing novel gene therapies for the treatment of cancer. The company has developed Ad-REIC, a proprietary adenoviral vector technology capable of delivery of the Reduced Expression in Immortalized Cells/Dickkopf-3 gene (REIC/Dkk-3 gene). Expression of the REIC/Dkk-3 gene is markedly downregulated in a broad range of human cancer cells. Momotaro-Gene has demonstrated that forced expression of REIC/Dkk-3 gene in tumor tissue induces immunogenic cell death of cancer cells and augmentation of anti-tumor immunity. In addition to the Phase 2 study with malignant pleural mesothelioma in combination with nivolumab, MTG201 is currently being investigated in patients with malignant pleural mesothelioma, hepatocellular carcinoma and glioblastoma multiforme in Japan.